Figure 5.

Kaplan-Meier curves for progression-free survival and tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in 43 patients with ovarian cancer. No significant differences in progression-free survival and TIMP-2 expression in the tumor compartment (A) and in cases with simultaneous tumor and stromal overexpression of TIMP-2 (C). Patients with enhanced immunoreactivity of TIMP-2 in the stromal compartment had an increased progression-free survival time (B). IRS, immunoreactive score.